Key result
An increase in platelet-derived microparticles 30 days after discharge was associated with a higher rate of 30-day major adverse cardiac events compared to a decrease (37.8% vs 16.7%, P=0.036).
Why the study?
Platelet-derived microparticle measurement adds prognostic implication in STEMI, but its long-term implication needed to be corroborated.
Is an increase in platelet-derived microparticles (PDMPs) 30 days after discharge associated with increased major adverse cardiac events in patients with STEMI?
Population
101 consecutive patients with STEMI
Comparison
Increased vs decreased PDMPs at 30 days post-discharge compared with admission
Design
Cohort study
Follow-up
1 year after discharge
Authors
Loading...
May identify higher-risk post-STEMI patients; hypothesis-generating and requires prospective validation before clinical adoption.
Cohort (n=101)
Is an increase in platelet-derived microparticles (PDMPs) 30 days after discharge associated with increased major adverse cardiac events in patients with STEMI?
Absolute Event Rate: 37.8% vs 16.7%
p-value: p=0.036
A persistent increase in platelet-derived microparticles 30 days after a STEMI event is associated with a higher risk of 30-day postdischarge major adverse cardiac events.
Hartopo et al. (2020) conducted a cohort in ST-elevation acute myocardial infarction (STEMI) (n=101). Increased platelet-derived microparticles (PDMPs) vs. Decreased PDMPs was evaluated on 30-day postdischarge major adverse cardiac events (MACE) (p=0.036). An increase in platelet-derived microparticles 30 days after discharge was associated with a higher rate of 30-day major adverse cardiac events compared to a decrease (37.8% vs 16.7%, P=0.036).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: